Preliminary imaging results using In-111 labeled CYT-356 (Prostascint(TM)) in the detection of recurrent prostate cancer

Clinical Nuclear Medicine

Volumn 21, Issue 10, 1996, Pages 759-767

  Sodee, D Bruce ^a   Conant, Ridgely ^a   Chalfant, Marshall ^a   Miron, Stefan ^a   Klein, Eric ^b   Bahnson, Robert ^c   Spirnak, J Patrick ^a   Carlin, Bruce ^d   Bellon, Errol M ^a   Rogers, Barbara ^e  

^a METROHEALTH MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Cytogen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE; CAPROMAB PENDETIDE IN 111; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; HUMAN; IMMUNOSCINTIGRAPHY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METASTASIS; PROSTATE CANCER; PROSTATECTOMY;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 10244228056     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199610000-00002     Document Type: Article

References (22)

1. Boring CC, Squires TS, Tong T, et al: CA, Cancer Stat 44:7, 1994.
2. Murphy GP, Natarajan N, Pontes JE, et al: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127:928, 1982.
3. Mettlin C, Jones GW, Averete H, et al: Defining and updating the American Cancer Society Guidelines for the Cancer Related Check-Up: prostate and endometrial cancers. CA Cancer J Clin 43:42, 1993.
4. Scardino PT: Early detection of prostate cancer. Urol Clin N Am 126:635, 1989.
5. Carion G, Vuong-Ngog P, Merran S, et al: Correlations between radiography, ultrasonography, computed tomography and pathologic findings in prostatic disease. Urology 26:599, 1985.
6. Mukamel E, Hannah J, Barbaric Z, et al: The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging. Urology 136:1231, 1986.
7. Heiken JP, Forman HP, Brown JJ: Neoplasms of the bladder, prostate and testis. Radiol Clin North Am 32:81, 1994.
8. Hricak H, Dooms GC, Jeffrey RB, et al: Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162:331, 1987.
9. Gervasi LA, Mata J, Easley JD, et al: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142:332, 1989.
10. Saitoh H, Yoshida K, Uchijima Y, et al: Two different lymph node metastatic patterns of a prostatic cancer. Cancer 65:1843, 1990.
11. Spencer JA, Golding SJ: Patterns of lymphatic metastases at recurrence of prostate cancer: CT findings. Clin Radiol 49:404, 1994.
12. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152:1490, 1994.
13. Oyen R, Van Poppel H, Ameye F, et al: Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine needle aspiration biopsy prospective study of 285 patients. Radiology 190:315, 1994.
14. 111Indium-labeled monoclonal antibody CYT-356. J Urol 152:1952, 1994.
15. Oefelein MG, Kaul K, Herz B, et al: Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol 155:238, 1996.
16. Fowler JE, et al: Histology of vesicourethral biopsies with detectable PSA after radical prostatectomy. J Urol (Abstract 116) 151:256A, 1994.
17. Haseman MK, Reed NL: Monoclonal antibody imaging improves detection of occult prostate cancer. Abstract Central Chapter Meeting, Cleveland, OH, April, 1995. Sutter General Hospital, Sacramento, CA.
18. Sirci SN, Petrylak DP, Fawwaz RA, et al: Detection of occult residual or recurrent prostate cancer in the prostate bed with IN-111 CYT-356 using a revised imaging protocol. Proceedings of the 42nd Annual Meeting, May 4, No. 28:9P, 1995.
19. Maguire RT, Pascucci VL, Maroli AN, et al: Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer: results with site-specific immunoconjugates. Cancer Suppl 72:3453, 1993.
20. Hill T, Horlik B, Hinkle G, et al: SPECT imaging of prostate carcinoma using a monoclonal antibody, Indium-111 CYT-356. J Nucl Med, Proceedings of the 42nd Annual Meeting, May 4, No. 27:9P, 1995.
21. 111Indium labeled CYT-358 for the detection of occult prostate cancer recurrence. J Urol 152:1490, 1994.
22. Maguire RT: IN-111 Capromab Pendetide (ProstaScint™) for presurgical staging of patients with prostate cancer. J Nucl Med, Proceedings of the 42nd Annual Meeting, May 4, No. 29:10P, 1995.